HC Wainwright Cuts BioNTech (NASDAQ:BNTX) Price Target to $130.00
by Danessa Lincoln · The Markets DailyBioNTech (NASDAQ:BNTX – Free Report) had its price target decreased by HC Wainwright from $140.00 to $130.00 in a report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for BioNTech’s Q1 2026 earnings at ($2.41) EPS, Q2 2026 earnings at ($2.43) EPS, Q3 2026 earnings at $0.69 EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($4.57) EPS.
A number of other analysts also recently commented on the stock. Canaccord Genuity Group restated a “buy” rating and set a $171.00 price target on shares of BioNTech in a research report on Wednesday, March 11th. Raymond James Financial reiterated an “outperform” rating on shares of BioNTech in a research note on Tuesday, March 10th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of BioNTech in a report on Tuesday, March 17th. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research report on Friday, January 9th. Finally, Wall Street Zen lowered BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $133.07.
Check Out Our Latest Analysis on BNTX
BioNTech Stock Performance
BNTX stock opened at $91.18 on Tuesday. The company has a 50-day simple moving average of $101.78 and a 200 day simple moving average of $101.26. The company has a market capitalization of $22.92 billion, a P/E ratio of -17.40 and a beta of 1.58. The company has a quick ratio of 7.49, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. BioNTech has a fifty-two week low of $79.52 and a fifty-two week high of $124.00.
Institutional Trading of BioNTech
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Kennedy Capital Management LLC raised its holdings in shares of BioNTech by 0.8% during the 2nd quarter. Kennedy Capital Management LLC now owns 16,422 shares of the company’s stock valued at $1,748,000 after purchasing an additional 127 shares in the last quarter. Larson Financial Group LLC boosted its holdings in BioNTech by 86.4% in the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares in the last quarter. Probity Advisors Inc. increased its position in BioNTech by 5.7% during the third quarter. Probity Advisors Inc. now owns 2,506 shares of the company’s stock worth $247,000 after buying an additional 135 shares during the last quarter. Mackenzie Financial Corp increased its position in BioNTech by 4.0% during the third quarter. Mackenzie Financial Corp now owns 4,290 shares of the company’s stock worth $418,000 after buying an additional 165 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in BioNTech by 40.8% during the third quarter. GAMMA Investing LLC now owns 784 shares of the company’s stock valued at $77,000 after buying an additional 227 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors.
BioNTech News Summary
Here are the key news stories impacting BioNTech this week:
- Positive Sentiment: HC Wainwright kept a “Buy” rating and a $130 price objective while raising its Q3 2026 EPS estimate to $0.69 (up from a prior negative forecast), which supports upside expectations for later‑year results. HC Wainwright Lowers BioNTech Price Target
- Positive Sentiment: Balance sheet metrics remain a cushion: very low debt‑to‑equity (~0.01) and high liquidity ratios (quick ratio ~7.49, current ratio ~7.54), which reduces near‑term solvency concerns amid uneven near‑term vaccine revenue. No external link
- Neutral Sentiment: Technical/liquidity context: trading volume was below the stock’s average and the share price remains under both the 50‑ and 200‑day moving averages, suggesting the rally may be tentative without follow‑through buying. No external link
- Negative Sentiment: Pfizer and BioNTech halted recruitment for a large U.S. trial of their updated COVID‑19 vaccine due to low enrollments — a near‑term pipeline setback that reduces the chance of near‑term trial data and future commercial upside from that program. Reuters: Pfizer, BioNTech halt US COVID vaccine study
- Negative Sentiment: HC Wainwright reduced near‑term (Q1, Q2, Q4) and full‑year FY2026 EPS estimates substantially (FY2026 now at –$4.57 vs prior –$3.63), and lowered its price target; those cuts reflect weaker near‑term revenue expectations and likely weighed on sentiment despite the maintained “Buy” rating. HC Wainwright Lowers BioNTech Price Target
- Negative Sentiment: Multiple outlets report the same trial stoppage (Reuters, MSN, Seeking Alpha, ThePharmaLetter), reinforcing the market view that enrollment and demand for updated COVID shots remain suppressed. ThePharmaLetter: COVID vaccine trial scrapped
About BioNTech
BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.
BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.